Article Text

Download PDFPDF

Letter
Neonatal randomised point-of-care trials are feasible and acceptable in the UK: results from two national surveys
  1. Christopher Gale,
  2. Neena Modi
  3. on behalf of the WHEAT trial development group
    1. Section of Neonatal Medicine, Department of Medicine, Imperial College London, Chelsea and Westminster Hospital campus, London, UK
    1. Correspondence to Professor Neena Modi, Section of Neonatal Medicine, Department of Medicine, Imperial College London, Chelsea and Westminster Hospital campus, 369 Fulham Road, London SW10 9NH, UK; n.modi{at}imperial.ac.uk

    Statistics from Altmetric.com

    Request Permissions

    If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.

    Randomised point-of-care trials (POCT)1 or registry trials2 offer a potentially efficient, convenient and cost-effective alternative to conventional randomised controlled trials. By using information present in an existing database, registry or electronic patient record (EPR), POCT eliminate the need for duplicative data collection.1 Neonatal medicine is well placed to use this methodology; an existing national resource, the National Neonatal Research Database (NNRD), holds detailed data extracted from the neonatal EPR of all National Health Service neonatal units in England, Wales and Scotland; contributing units are known as the UK Neonatal Collaborative (UKNC).

    We assessed the acceptability of neonatal POCT using the NNRD in two surveys. In the first (March–June 2014), we emailed all English UKNC leads, proposed a neonatal POCT and asked whether their unit would be willing to participate. In the second, we examined attitudes towards the neonatal EPR. We emailed neonatal trainees (n=108) and lead nurses, and asked them …

    View Full Text